Ruxolitinib Phosphate API Suppliers & Bulk Manufacturers
Available Forms: API (drug substance)
Available Strengths: USP grade or in-house specification
Reference Brands: Jakafi, Jakavi
Category: Active Pharmaceutical Ingredient
Ruxolitinib phosphate is a JAK1/JAK2 inhibitor used in tablets for myelofibrosis, polycythaemia vera and graft-versus-host disease. It is sourced by formulators, CDMOs and R&D teams.
Manufacture or export Ruxolitinib Phosphate API? List it or send an offer →
Product Description:
Ruxolitinib is a kinase inhibitor of Janus kinases JAK1 and JAK2, which carry signals for blood cell production and inflammation. In tablet form it is approved for intermediate or high-risk myelofibrosis, for polycythaemia vera in adults who have had an inadequate response to or cannot tolerate hydroxyurea, and for steroid-refractory acute graft-versus-host disease and chronic graft-versus-host disease after one or two lines of systemic therapy (reference brands: Jakafi, Jakavi).
Specification at a glance
| Traded form | Phosphate salt of the (R)-enantiomer; white to off-white to light pink powder, soluble in aqueous buffers from pH 1 to 8 |
|---|---|
| CAS number | 1092939-17-7 |
| Molecular formula | C17H18N6·H3PO4 |
| Molecular weight | 404.36 g/mol |
| Pharmacopoeia | Unverified. USP's April 2024 priority list shows ruxolitinib phosphate among entries removed from the list since July 2023 and still lists ruxolitinib tablets and cream as new monographs to develop; check the current USP–NF. No Ph. Eur., JP, BP or IP monograph found (unverified). |
Regulatory files and timing
The FDA list of Drug Master Files (third quarter 2026) shows 27 active Type II API DMFs for this molecule. There is a fair choice of sources, so compare documents and impurity profiles, not just price. For Europe, ask whether the supplier holds a CEP or an EU ASMF and, for imports into the EU, a written confirmation.
Generic or biosimilar entry. United States: Patent expiry; entry not confirmed (late 2028). European Union: Patent expiry; entry not confirmed (mid 2028).
Handling and quality points
Ruxolitinib is a single (R)-enantiomer, so chiral purity is a core part of the specification. It is a potent kinase inhibitor and is commonly treated as a high-potency compound in manufacture, with containment and cleaning data expected. Ask for nitrosamine and mutagenic impurity assessments and confirm the phosphate salt stoichiometry and crystal form.
Send an API enquiry All specialty APIs
Brand names are trademarks of their respective owners and identify the reference medicine only. Information is general and was checked in October 2026; confirm specifications and filings with the supplier before purchase.
Ruxolitinib Phosphate API — third party manufacturing & bulk supply
Ruxolitinib Phosphate API is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Ruxolitinib Phosphate API is supplied as API (drug substance) — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Ruxolitinib Phosphate API listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Ruxolitinib Phosphate API →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
The usual starting set is the GMP certificate, certificate of analysis and specification, plus a US DMF letter of access and EU ASMF or CEP where available. Chiral purity data, salt and solid-form characterisation and stability results are standard. Buyers also ask for a nitrosamine risk assessment and mutagenic impurity review.
The approved products use the phosphate, which is soluble across pH 1 to 8 and gives a well-characterised crystalline solid. Switching to the free base or another salt would need bridging data, so match the reference salt unless you have a clear development reason not to.
Yes. We introduce licensed formulators, CDMOs and R&D teams to GMP-compliant ruxolitinib phosphate manufacturers, with document checks carried out first. Your company is not named to anyone until both sides agree.
Related Products
Tenofovir Alafenamide Fumarate API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Descovy, Vemlidy, Odefsey, Genvoya, Biktarvy
View DetailsExatecan API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Enhertu, Datroway
View DetailsAxitinib API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Inlyta
View DetailsIxazomib Citrate API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Ninlaro
View DetailsBaricitinib API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Olumiant
View DetailsIvabradine Hydrochloride API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Corlanor, Procoralan
View DetailsFerric Derisomaltose API
Strength:
Supplied to an in-house or pharmacopoeial specification
Form: API (drug substance)
Reference Brands: Monoferric, Monofer
View DetailsTrabectedin API
Strength:
USP grade or in-house specification
Form: API (drug substance)
Reference Brands: Yondelis
View DetailsUsually answered within 48 hours | GMP documents shared before you commit